Long Acting Buprenorphine Development and Manufacturing for Opioid Substitution Therapy (Unitaid)

WHO
Long Acting Buprenorphine Development and Manufacturing for Opioid Substitution Therapy (Unitaid) Request for information

Reference: UNITAID/RFI/LABUP/2020
Beneficiary countries or territories: Switzerland
Published on: 25-Mar-2021
Deadline on: 23-Apr-2021 17:00 (GMT 1.00)

Description

Unitaid is an international organization that invests in innovations for the prevention, diagnosis and treatment of HIV and coinfections/comorbidities, tuberculosis and malaria more quickly, affordably and effectively, enabling their scaled-up use in low and middle-income countries. Unitaid’s investments establish the viability of health innovations, allowing partner organizations to make them widely available.

This request for Information (RfI) is issued to provide an opportunity for industry players and manufacturers to provide information on Long Acting formulations of Buprenorphine.

We kindly invite you to participate in this RfI though the enclosed questionnaire, to be submitted to Unitaid-RFI@who.int by 23 April 2021, 17:00 (CET). Please note, any information submitted in response to this RfI is provided on a voluntary basis. Please also take note of disclaimer text on the RfI cover page.

We look forward to engaging with you.

Kind regards,

Unitaid team